WCCT Global Plan for Ethnobridging Clinical Studies and Diabetes

COSTA MESA, Calif., August 16, 2013/PRWeb/–WCCT Global, a contract research organization headquartered in Southern California, announced a plan for diabetes Ethnobridging clinical studies with a focus aimed to support China-based pharmaceutical companies. WCCT Global has been an industry leader in helping sponsors from Asia to initiate their new product development programs in the US. And now that China is becoming the country with the highest population of T2DM in the world, WCCT Global is placing an emphasis on supporting the Chinese Pharma Industry in the development of new T2DM drugs for China and exportation to other markets worldwide. WCCT Global has extensive research experience in both ethnobridging and T2DM clinical research and is the worldwide market leader in conducting ethnic sensitivity studies in various Asian populations.

WCCT Global is located in Southern California which is richly populated by many diverse populations. However, 17% of all Asian Americans are living in Southern California, making it the largest Asian population in the U.S. Therefore, WCCTG can reach out to Japanese, Chinese, Korean, Vietnamese, Philippine, and Taiwanese and screen large numbers for either healthy volunteer or patient studies. WCCT Global’s VP of Business Development Talia Nikolao stated, “Our capabilities in Ethnobridging clinical studies is the reason why many of our clients come back time and time again to have WCCT Global conduct their clinical clinical research programs.”

By Matt Miller